PO

Insulet

- NASDAQ:PODD
Last Updated 2021-09-24

Indeed Snapshot

Track Insulet reviews on Indeed to uncover insights on employee sentiment
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Sector Industry
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 29th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 29th, 2021 07:26AM Aug 29th, 2021 07:26AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 28th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 28th, 2021 07:22AM Aug 28th, 2021 07:22AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 27th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 27th, 2021 07:25AM Aug 27th, 2021 07:25AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 26th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 26th, 2021 06:31AM Aug 26th, 2021 06:31AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 22nd, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 22nd, 2021 07:27AM Aug 22nd, 2021 07:27AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 21st, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 21st, 2021 07:16AM Aug 21st, 2021 07:16AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 20th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 20th, 2021 07:28AM Aug 20th, 2021 07:28AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 19th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 19th, 2021 07:02AM Aug 19th, 2021 07:02AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 18th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 18th, 2021 07:18AM Aug 18th, 2021 07:18AM Health Care Health Care Equipment & Services
nasdaq:podd https://www.indeed.com/cmp/insulet-corporation Aug 17th, 2021 12:00AM Open Insulet Corporation Pharmaceutical & Biotechnology Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. On July 1, 2018, Insulet assumed direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. RRv1_100M_500M Shacey Petrovic 3.10 60.0 59.0 60.0 62.0 59.0 58.0 54.0 70.0 55.0 56.0 58.0 63.0 65.0 58.0 122.00 122.00 2.70 3.50 2.60 2.50 2.90 31.00 About two weeks 33.00 MEDIUM 33.00 FAVORABLE Aug 17th, 2021 08:00AM Aug 17th, 2021 08:00AM Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.